Phenomenology of Levodopa-Induced Dyskinesia
暂无分享,去创建一个
Kallol Ray Chaudhuri | Panagiotis Zis | Michael Samuel | K. Chaudhuri | M. Samuel | Michael Samuel | P. Zis
[1] A. Barbeau. Dopamine and basal ganglia diseases. , 1961, Archives of neurology.
[2] A. Carlsson,et al. The occurrence, distribution and physiological role of catecholamines in the nervous system. , 1959, Pharmacological reviews.
[3] A. Lees,et al. The impact of treatment with levodopa on Parkinson's disease. , 1980, The Quarterly journal of medicine.
[4] C. Marsden,et al. Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study. , 1994, Clinical neuropharmacology.
[5] John Seibyl,et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. , 2004, Archives of neurology.
[6] S. Shapiro. ALLOPURINOL AND BONE-MARROW DEPRESSION , 1974 .
[7] L. Cote,et al. Painful dystonic spasms in Parkinson's disease. , 1984, Advances in neurology.
[8] G. Deuschl,et al. Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review , 2013, Journal of Neurology.
[9] Silvia Vázquez-Fernández del Pozo,et al. Motor complications in Parkinson's disease: Ten year follow‐up study , 2010, Movement disorders : official journal of the Movement Disorder Society.
[10] I. Shoulson,et al. Duodenal delivery of levodopa for on‐off fluctuations in parkinsonism: Preliminary observations , 1986, Annals of neurology.
[11] J A Obeso,et al. Motor complications associated with chronic levodopa therapy in Parkinson's disease. , 1989, Neurology.
[12] Angelo Antonini,et al. Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management , 2009, Expert review of neurotherapeutics.
[13] M. Hallett,et al. Phenomenology and classification of dystonia: A consensus update , 2013, Movement disorders : official journal of the Movement Disorder Society.
[14] Y. Michotte,et al. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations. , 1989, Neurology.
[15] P. LeWitt. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.
[16] J. Obeso,et al. Impairment of brain vessels may contribute to mortality in patients with Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.
[17] W. Oertel,et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study , 2006, Movement disorders : official journal of the Movement Disorder Society.
[18] Agid Yves. Levodopa‐induced dyskinesia , 1992 .
[19] C. Marsden,et al. COMPLICATED RESPONSE FLUCTUATIONS IN PARKINSON'S DISEASE: RESPONSE TO INTRAVENOUS INFUSION OF LEVODOPA , 1982, The Lancet.
[20] F. Mcdowell,et al. A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance. , 1989, Journal of neurology, neurosurgery, and psychiatry.
[21] Tom Robinson,et al. Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment , 2007, Postgraduate Medical Journal.
[22] A. Barbeau. L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. , 1969, Canadian Medical Association journal.
[23] J. Obeso,et al. Levodopa‐induced dyskinesias in Parkinson's disease: Clinical and pharmacological classification , 1992, Movement disorders : official journal of the Movement Disorder Society.
[24] C. Tanner,et al. Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.
[25] H. Tan,et al. Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease , 2014, The International journal of neuroscience.
[26] T. Chase,et al. Pathogenesis of dyskinesias in parkinson's disease , 1989, Annals of neurology.
[27] M. Rich,et al. Respiratory dyskinesia. An underrecognized phenomenon. , 1994, Chest.
[28] P. Boon,et al. The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease , 2007, Clinical Neurology and Neurosurgery.
[29] C. Goetz,et al. Levodopa‐induced dyskinesias , 2007, Movement disorders : official journal of the Movement Disorder Society.
[30] W. Jost. Gastrointestinal dysfunction in Parkinson's Disease , 2010, Journal of the Neurological Sciences.
[31] Neeraj Kumar,et al. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. , 2006, Archives of neurology.
[32] Richard S. J. Frackowiak,et al. Inhibition of L‐{18F}fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography , 1986, Annals of neurology.
[33] A. Albanese,et al. Levodopa-induced dyskinesias and their management , 2008, Journal of Neurology.
[34] C. Clarke,et al. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. , 2009, Parkinsonism & related disorders.
[35] S. Reines,et al. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease. , 1989, Neurology.
[36] R. Frowein,et al. Über die Wirkungen des L-Dopa beim Menschen und deren Beeinflussung durch Reserpin, Chlorpromazin, Iproniazid und Vitamin B6 , 1960, Klinische Wochenschrift.
[37] A. Schrag,et al. Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. , 2012, Journal of Parkinson's disease.
[38] A. Carlsson,et al. On the presence of 3-hydroxytyramine in brain. , 1958, Science.
[39] R. Hauser,et al. Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life, and Treatments , 2008, European Neurology.
[40] W. Poewe,et al. Dystonia in parkinson's disease: Clinical and pharmacological features , 1988, Annals of neurology.
[41] R. Djaldetti,et al. Patient and caregiver perceptions of the social impact of advanced Parkinson’s disease and dyskinesias , 2012, Journal of Neural Transmission.
[42] O. Hornykiewicz,et al. Clinical–Pathological study of levodopa complications , 2002, Movement disorders : official journal of the Movement Disorder Society.
[43] M. Ceccaldi,et al. Nonmotor fluctuations in Parkinson’s disease: Frequent and disabling , 2002, Neurology.
[44] A. Bentivoglio,et al. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life. , 2012, European review for medical and pharmacological sciences.
[45] A. Barbeau. Preliminary observations on abnormal catecholamine metabolism in basal ganglia diseases , 1960, Neurology.
[46] J. Jankovic,et al. Respiratory dyskinesia in Parkinson's disease , 1986, Neurology.
[47] A. Friedman. Levodopa-induced dyskinesia: clinical observations , 2004, Journal of Neurology.
[48] L. Lopiano,et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome , 2007, Movement disorders : official journal of the Movement Disorder Society.
[49] N. Quinn. Classification of fluctuations in patients with Parkinson's disease , 1998, Neurology.
[50] J. Keyser,et al. L‐dopa‐induced respiratory disturbance in Parkinson's disease suppressed by tiapride , 1985, Neurology.
[51] E. Zehr,et al. Ballistic movement: muscle activation and neuromuscular adaptation. , 1994, Canadian journal of applied physiology = Revue canadienne de physiologie appliquee.
[52] L. Grégoire,et al. Risk Factors for Peak Dose Dyskinesia in 100 Levodopa-treated Parkinsonian Patients , 1996, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[53] Joseph Jankovic,et al. Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations , 2005, Movement disorders : official journal of the Movement Disorder Society.
[54] T. Laar. Levodopa-Induced Response Fluctuations in Patients with Parkinson’s Disease , 2003 .
[55] Alberto J Espay,et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. , 2013, Parkinsonism & related disorders.
[56] J. Nutt. On‐off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics , 1987, Annals of neurology.
[57] E. Melamed. Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease. , 1979, Archives of neurology.
[58] O. Hornykiewicz,et al. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. , 1998, Klinische Wochenschrift.
[59] C. Marsden,et al. Control of on/off phenomenon by continuous intravenous infusion of levodopa , 1984, Neurology.
[60] J. Bennett,et al. Suppression of dyskinesias in advanced Parkinson's disease , 1993, Neurology.
[61] Extended-release carbidopa-levodopa in Parkinson's disease , 2013, The Lancet Neurology.
[62] J. Jankovic,et al. Parkinson's Disease and Movement Disorders , 1988 .
[63] M. Mark,et al. Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study. , 1988, Clinical neuropharmacology.
[64] L. Wilkins. Pathogenesis and Treatment of Parkinsonism , 1959, Neurology.
[65] P. Burkhard,et al. Levodopa‐induced ocular dyskinesia in Parkinson's disease , 2007, European journal of neurology.
[66] Megan M. Romer,et al. Impact of pramipexole on the onset of levodopa‐related dyskinesias , 2007, Movement disorders : official journal of the Movement Disorder Society.
[67] T. Müller. Motor complications, levodopa metabolism and progression of Parkinson's disease , 2011, Expert opinion on drug metabolism & toxicology.
[68] E. Tolosa,et al. Immediate-release and controlled-release carbidopa/levodopa in PD , 1999, Neurology.
[69] P. Thompson,et al. Disordered respiration as a levodopa‐induced dyskinesia in Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.
[70] M. Muenter,et al. Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.
[71] L. Vacca,et al. Motor fluctuations in levodopa treatment: clinical pharmacology. , 1996, European Neurology.
[72] D. Brooks,et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.
[73] John Seibyl,et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. , 2000, JAMA.
[74] N. Van Blercom,et al. Levodopa‐induced ocular dyskinesias in Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.
[75] T. Sourkes,et al. Excretion of Dopamine in Diseases of Basal Ganglia , 1961, Science.
[76] W. Poewe,et al. The clinical spectrum of levodopa-induced motor complications , 2010, Journal of Neurology.
[77] Anthony E. Lang,et al. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa , 1996 .
[78] M. Stacy,et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial , 2013, The Lancet Neurology.
[79] M. Muenter,et al. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease. , 1988, Mayo Clinic proceedings.
[80] D. Nyholm,et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease , 2005, Neurology.
[81] M. Muenter,et al. Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease. , 1977, Mayo Clinic proceedings.
[82] O. Sacks,et al. Side-effects of L-dopa in postencephalic parkinsonism. , 1970, Lancet.
[83] Kelly L. Sullivan,et al. Levodopa-induced Dyskinesia in Parkinson’s disease: Epidemiology, etiology, and treatment , 2007, Current neurology and neuroscience reports.
[84] M. Hely,et al. Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years , 2005, Movement disorders : official journal of the Movement Disorder Society.
[85] H. Lennernäs,et al. Optimizing Levodopa Pharmacokinetics: Intestinal Infusion Versus Oral Sustained-Release Tablets , 2003, Clinical neuropharmacology.
[86] Werner Poewe,et al. Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa , 2007, Movement disorders : official journal of the Movement Disorder Society.
[87] Y. Agid,et al. Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology , 1994, Movement disorders : official journal of the Movement Disorder Society.
[88] E. Tolosa,et al. Immediate-release and controlled-release carbidopa/levodopa in PD A 5-year randomized multicenter study , 1999 .
[89] W. Oertel,et al. Continuous Jejunal Levodopa Infusion in Patients With Advanced Parkinson Disease: Practical Aspects and Outcome of Motor and Non-motor Complications , 2008, Clinical neuropharmacology.